Shilpa Medicare (SHILPAMED) | Stock Overview & Key Data
Shilpa Medicare Performance Comparison
Stock Range
Today's Range
Low: ₹856.00
High: ₹913.70
on August 13, 2025
52 Week Range
Low: ₹555.00
High: ₹1,000.00
on April 7, 2025
on June 16, 2025
All-Time High: ₹35,595.00 on October 30, 2023
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR80.7B
EPS
8.07
P/E Ratio (TTM)
102.23
Forward P/E
21.98
P/B Ratio
3.41
PEG Ratio
0.86
Div. Yield
N/A
ROE
3.76%
Beta
0.138
Debt to Equity
24.87
Financial Highlights
Profitability
Gross Margin
68.42%
Operating Margin
14.50%
Profit Margin
6.09%
Returns and Earnings
Return on Assets (TTM)
3.98%
Return on Equity (TTM)
3.76%
EBITDA
INR3.4B
Net Income (TTM)
INR782.9M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR131.55
Quarterly Revenue Growth (YoY)
12.70%
Quarterly Earnings Growth (YoY)
-40.80%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Shilpa Medicare SHILPAMED | 80.68B Mid-cap | 0.96% | -3.94% | 33.72% | 31.48% | 6.44% | 29.29% | 125.52% | 49.02% |
| Sun Pharmaceutical SUNPHARMA | 3.81T Large-cap | -0.61% | -3.59% | -3.80% | -4.23% | -14.17% | -7.71% | 78.44% | 202.13% |
| Divi's Laboratories DIVISLAB | 1.59T Large-cap | -6.99% | -12.06% | 0.32% | -0.15% | -1.84% | 28.64% | 61.27% | 83.57% |
| Alembic APLLTD | 184.02B Mid-cap | 0.11% | -8.05% | 7.72% | 12.11% | -9.68% | -13.03% | 45.37% | -5.19% |
| Jubilant Pharmova JUBLPHARMA | 174.27B Mid-cap | -3.74% | -9.78% | 22.53% | 7.88% | -0.25% | 29.21% | 219.24% | 77.55% |
| Neuland Laboratories NEULANDLAB | 170.94B Mid-cap | 1.17% | -10.78% | 3.26% | -4.89% | -9.20% | 13.98% | 1,083.81% | 1,293.93% |
Ownership & Short Interest
Insider Ownership
55.32%
Institutional Ownership
9.70%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
48K
Average 90-Day Volume
63K
Shilpa Medicare Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Shilpa Medicare would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SHILPAMED's 52-week high and low?
- In the last 52 weeks, Shilpa Medicare reached a high of ₹1,000.00 (on June 16, 2025) and a low of ₹555.00 (on April 7, 2025).
- What is the market cap and P/E ratio for SHILPAMED?
- Curious about Shilpa Medicare's size and valuation? Its market capitalization stands at 80.68B. When it comes to valuation, the P/E ratio (trailing twelve months) is 102.23, and the forward P/E (looking ahead) is 21.98.
- Does SHILPAMED pay dividends? If so, what's the yield?
- As for dividends, Shilpa Medicare isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Shilpa Medicare's main competitors or similar companies to consider before investing?
When looking at Shilpa Medicare, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.81T Healthcare Drug Manufacturers - Specialty & Generic -7.71% 78.44% Divi's Laboratories
DIVISLAB1.59T Healthcare Drug Manufacturers - Specialty & Generic 28.64% 61.27% Alembic
APLLTD184.02B Healthcare Drug Manufacturers - Specialty & Generic -13.03% 45.37% Jubilant Pharmova
JUBLPHARMA174.27B Healthcare Drug Manufacturers - Specialty & Generic 29.21% 219.24% Neuland Laboratories
NEULANDLAB170.94B Healthcare Drug Manufacturers - Specialty & Generic 13.98% 1,083.81% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Shilpa Medicare Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Shilpa Medicare's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 3.76%, the Debt to Equity ratio from the most recent quarter is 24.87, and its Gross Profit Margin stands at 68.42%.
- What is the recent revenue and earnings growth for SHILPAMED?
- Looking at Shilpa Medicare's growth, its revenue over the trailing twelve months (TTM) was INR13B. Compared to the same quarter last year (YoY), quarterly revenue grew by 12.70%, and quarterly earnings saw a YoY growth of -40.80%.
- How much of SHILPAMED stock is held by insiders and institutions?
- Wondering who owns Shilpa Medicare stock? Company insiders (like executives and directors) hold about 55.32% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 9.70%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.